Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

Todd Neale

December 29, 2021

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

News Daily News

Statins Underprescribed in PAD Before and After Interventions

L.A. McKeown

December 03, 2021

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

Shelley Wood

September 13, 2021

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

L.A. McKeown

September 07, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Yael L. Maxwell

July 01, 2021

New CV Surgery Guidelines Shift Focus to ‘Blood Management’

News Daily News

CV Surgery Societies Urge Shift to ‘Blood Management’

Yael L. Maxwell

June 30, 2021

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

Advertisement

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Statins Underprescribed in PAD Before and After Interventions

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

More DAPT Duration Data, More Calls to Tailor to Individual Patients

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Women Stand to Gain the Most From Standardized STEMI Protocols

Long-term Anticoagulation After Unprovoked VTE: New Insights

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

CV Surgery Societies Urge Shift to ‘Blood Management’

OMT Boosts Survival in Revascularized Patients at 10 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content